Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review)
- Authors:
- Danhua Wang
- Yiwen Sang
- Tao Sun
- Piaoping Kong
- Lingyu Zhang
- Yibei Dai
- Ying Cao
- Zhihua Tao
- Weiwei Liu
-
Affiliations: Department of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China - Published online on: March 10, 2021 https://doi.org/10.3892/ijo.2021.5200
- Article Number: 20
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Orso F, Quirico L, Dettori D, Coppo R, Virga F, Ferreira LC, Paoletti C, Baruffaldi D, Penna E and Taverna D: Role of miRNAs in tumor and endothelial cell interactions during tumor progression. Semin Cancer Biol. 60:214–224. 2020. View Article : Google Scholar | |
|
Iwakawa HO and Tomari Y: The functions of MicroRNAs: mRNA decay and translational repression. Trends Cell Biol. 25:651–665. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wightman B, Ha I and Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 75:855–862. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gebert LFR and MacRae IJ: Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 20:21–37. 2019. View Article : Google Scholar : | |
|
Treiber T, Treiber N and Meister G: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019. View Article : Google Scholar | |
|
Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K and Shiekhattar R: TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 436:740–744. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, Chen M, Wang X, Kang Y, Zhou Y, et al: Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma. Cancer Res. 75:4384–4397. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chang KW, Kao SY, Wu YH, Tsai MM, Tu HF, Liu CJ, Lui MT and Lin SC: Passenger strand miRNA miR-31* regulates the phenotypes of oral cancer cells by targeting RhoA. Oral Oncol. 49:27–33. 2013. View Article : Google Scholar | |
|
Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K and Kawada N: MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut. 61:1600–1609. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yasmeen S, Kaur S, Mirza AH, Brodin B, Pociot F and Kruuse C: miRNA-27a-3p and miRNA-222-3p as novel modulators of phosphodiesterase 3a (PDE3A) in cerebral microvascular endothelial cells. Mol Neurobiol. 56:5304–5314. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gulluoglu S, Tuysuz EC, Kuskucu A, Ture U, Atalay B, Sahin F and Bayrak OF: The potential function of microRNA in chordomas. Gene. 585:76–83. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu C, Liu Z, Ma L, Pei C, Qin L, Gao N, Li J and Yin Y: MiRNAs regulate oxidative stress related genes via binding to the 3'UTR and TATA-box regions: A new hypothesis for cataract pathogenesis. BMC Ophthalmol. 17:2–8. 2017. View Article : Google Scholar | |
|
Verjans R, Peters T, Beaumont FJ, van Leeuwen R, van Herwaarden T, Verhesen W, Munts C, Bijnen M, Henkens M, Diez J, et al: MicroRNA-221/222 family counteracts myocardial fibrosis in pressure overload-induced heart failure. Hypertension. 71:280–288. 2018. View Article : Google Scholar | |
|
Wei F, Ma C, Zhou T, Dong X, Luo Q, Geng L, Ding L, Zhang Y, Zhang L, Li N, et al: Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. Mol Cancer. 16:132–147. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Coarfa C, Fiskus W, Eedunuri VK, Rajapakshe K, Foley C, Chew SA, Shah SS, Geng C, Shou J, Mohamed JS, et al: Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene. 35:2345–2356. 2016. View Article : Google Scholar | |
|
Liu L, Wang HJ, Meng T, Lei C, Yang XH, Wang QS, Jin B and Zhu JF: lncRNA GAS5 inhibits cell migration and invasion and promotes autophagy by targeting miR-222-3p via the GAS5/PTEN-signaling pathway in CRC. Mol Ther Nucleic Acids. 17:644–656. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jafri MA, Al-Qahtani MH and Shay JW: Role of miRNAs in human cancer metastasis: Implications for therapeutic intervention. Semin Cancer Biol. 44:117–131. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Alves Dos Santos K, Clemente Dos Santos IC, Santos Silva C, Gomes Ribeiro H, de Farias Domingos I and Nogueira Silbiger V: Circulating exosomal miRNAs as biomarkers for the diagnosis and prognosis of Colorectal Cancer. 22:3462020. | |
|
Fong M, Yan W, Ghassemian M, Wu X, Zhou X, Cao M, Jiang L, Wang J, Liu X, Zhang J and Wang SJ: Cancer-secreted miRNAs regulate amino-acid-induced mTORC1 signaling and fibroblast protein synthesis. EMBO Rep. 22:e512392020.PubMed/NCBI | |
|
Wang X, Liao X, Huang K, Zeng X, Liu Z, Zhou X, Yu T, Yang C, Yu L, Wang Q, et al: Clustered microRNAs hsa-miR-221-3p/hsa-miR-222-3p and their targeted genes might be prognostic predictors for hepatocellular carcinoma. J Cancer. 10:2520–2533. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Deng Z, Chen X, Cai J, Ma T, Zhong Q, Li R, Li L and Li T: Downregulation of miR-222-3p reverses doxorubicin-resistance in LoVo cells through upregulating forkhead box protein P2 (FOXP2) protein. Med Sci Monit. 25:2169–2178. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo J, Liu Q, Li Z, Guo H, Bai C and Wang F: miR-222-3p promotes osteosarcoma cell migration and invasion through targeting TIMP3. Onco Targets Ther. 11:8643–8653. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Che Q, Qiu H, Bao W, Chen X, Lu W, Li B and Wan X: Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERalpha. PLoS One. 9:e875632014. View Article : Google Scholar | |
|
Ostenfeld MS, Jensen SG, Jeppesen DK, Christensen LL, Thorsen SB, Stenvang J, Hvam ML, Thomsen A, Mouritzen P, Rasmussen MH, et al: miRNA profiling of circulating EpCAM(+) extracellular vesicles: Promising biomarkers of colorectal cancer. J Extracell Vesicles. 5:3402–3417. 2016. View Article : Google Scholar | |
|
Korabecna M, Koutova L and Tesarova P: The potential roles of vesicle-enclosed miRNAs in communication between macrophages and cancer cells in tumor microenvironment. Neoplasma. 64:406–411. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gasparello J, Papi C, Allegretti M, Giordani E, Carboni F, Zazza S, Pescarmona E, Romania P, Giacomini P, Scapoli C, et al: A distinctive microRNA (miRNA) signature in the blood of colorectal cancer (CRC) patients at surgery. Cancers (Basel). 12:24102020. View Article : Google Scholar | |
|
Pudova E, Krasnov G, Nyushko K, Kobelyatskaya A, Savvateeva M, Poloznikov A, Dolotkazin D, Klimina K, Guvatova Z, Simanovsky S, et al: miRNAs expression signature potentially associated with lymphatic dissemination in locally advanced prostate cancer. BMC Med Genomics. 13(Suppl 8): S1292020. View Article : Google Scholar | |
|
Jiang K, Li G, Chen W, Song L, Wei T, Li Z, Gong R, Lei J, Shi H and Zhu J: Plasma exosomal miR-146b-5p and miR-222-3p are potential biomarkers for lymph node metastasis in papillary thyroid carcinomas. Onco Targets Ther. 13:1311–1319. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fredsoe J, Rasmussen AKI, Mouritzen P, Borre M, Orntoft T and Sorensen KD: A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine. Int J Cancer. 145:2558–2567. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Cheng T, Zhao Y and Qu Y: HMGA1 exacerbates tumor progression by activating miR-222 through PI3K/Akt/MMP-9 signaling pathway in uveal melanoma. Cell Signal. 63:52019. View Article : Google Scholar | |
|
Zhang XF, Ye Y and Zhao SJ: LncRNA Gas5 acts as a ceRNA to regulate PTEN expression by sponging miR-222-3p in papillary thyroid carcinoma. Oncotarget. 9:3519–3530. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tan X, Tang H, Bi J, Li N and Jia Y: MicroRNA-222-3p associated with Helicobacter pylori targets HIPK2 to promote cell proliferation, invasion, and inhibits apoptosis in gastric cancer. J Cell Biochem. 119:5153–5162. 2018. View Article : Google Scholar | |
|
Ma S, Kong S, Gu X, Xu Y, Tao M, Shen L, Shen X and Ju S: As a biomarker for gastric cancer, circPTPN22 regulates the progression of gastric cancer through the EMT pathway. Cancer Cell Int. 21:442021. View Article : Google Scholar : PubMed/NCBI | |
|
Fu X, Li Y, Alvero A, Li J, Wu Q, Xiao Q, Peng Y, Hu Y, Li X, Yan W, et al: MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Oncotarget. 7:80633–80654. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rosignolo F, Memeo L, Monzani F, Colarossi C, Pecce V, Verrienti A, Durante C, Grani G, Lamartina L, Forte S, et al: MicroRNA-based molecular classification of papillary thyroid carcinoma. Int J Oncol. 50:1767–1777. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A, Merkel AL, Quint K and Ocker M: Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res. 318:1832–1843. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jahanbani I, Al-Abdallah A, Ali RH, Al-Brahim N and Mojiminiyi O: Discriminatory miRNAs for the management of papillary thyroid carcinoma and noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Thyroid. 28:319–327. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Denaro M, Ugolini C, Poma AM, Borrelli N, Materazzi G, Piaggi P, Chiarugi M, Miccoli P, Vitti P and Basolo F: Differences in miRNA expression profiles between wild-type and mutated NIFTPs. Endocr Relat Cancer. 24:543–553. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Borrelli N, Denaro M, Ugolini C, Poma AM, Miccoli M, Vitti P, Miccoli P and Basolo F: miRNA expression profiling of 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas. Mod Pathol. 30:39–51. 2017. View Article : Google Scholar | |
|
de Conti A, Ortega JF, Tryndyak V, Dreval K, Moreno FS, Rusyn I, Beland FA and Pogribny IP: MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis. Oncotarget. 8:88517–88528. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim BH, Hong SW, Kim A, Choi SH and Yoon SO: Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 107:505–510. 2013. View Article : Google Scholar | |
|
Zhang L, Huang Z, Zhang H, Zhu M, Zhu W, Zhou X and Liu P: Prognostic value of candidate microRNAs in gastric cancer: A validation study. Cancer Biomark. 18:221–230. 2017. View Article : Google Scholar | |
|
Rinnerthaler G, Hackl H, Gampenrieder SP, Hamacher F, Hufnagl C, Hauser-Kronberger C, Zehentmayr F, Fastner G, Sedlmayer F, Mlineritsch B and Greil R: miR-16-5p is a stably-expressed house-keeping MicroRNA in breast cancer tissues from primary tumors and from metastatic sites. Int J Mol Sci. 17:156–167. 2016. View Article : Google Scholar | |
|
Fredsoe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Hoyer S, Borre M, Orntoft TF and Sorensen KD: Diagnostic and prognostic MicroRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus. 4:825–833. 2018. View Article : Google Scholar | |
|
Fang R, Zhu Y, Hu L, Khadka VS, Ai J, Zou H, Ju D, Jiang B, Deng Y and Hu X: Plasma MicroRNA pair panels as novel biomarkers for detection of early stage breast cancer. Front Physiol. 9:1879–1880. 2018. View Article : Google Scholar | |
|
Fu Z, Qian F, Yang X, Jiang H, Chen Y and Liu S: Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer. Med Oncol. 31:164–175. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chang YA, Weng SL, Yang SF, Chou CH, Huang WC, Tu SJ, Chang TH, Huang CN, Jong YJ and Huang HD: A Three-MicroRNA signature as a potential biomarker for the early detection of oral cancer. Int J Mol Sci. 19:7582018. View Article : Google Scholar | |
|
Fredsoe J, Rasmussen AKI, Laursen EB, Cai Y, Howard KA, Pedersen BG, Borre M, Mouritzen P, Orntoft T and Sorensen KD: Independent validation of a diagnostic noninvasive 3-MicroRNA ratio model (uCaP) for prostate cancer in cell-free urine. Clin Chem. 65:540–548. 2019. View Article : Google Scholar | |
|
Uchino K, Takeshita F, Takahashi RU, Kosaka N, Fujiwara K, Naruoka H, Sonoke S, Yano J, Sasaki H, Nozawa S, et al: Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Mol Ther. 21:610–619. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tan X, Tang H, Bi J, Li N and Jia Y: MicroRNA-222-3p associated with Helicobacter pylori targets HIPK2 to promote cell proliferation, invasion, and inhibits apoptosis in gastric cancer. J Cell Biochem. 119:5153–5162. 2018. View Article : Google Scholar | |
|
Rosignolo F, Sponziello M, Giacomelli L, Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina L, Grani G, et al: Identification of thyroid-associated serum microRNA profiles and their potential use in thyroid cancer follow-up. J Endocr Soc. 1:3–13. 2017.PubMed/NCBI | |
|
Ulivi P, Petracci E, Marisi G, Baglivo S, Chiari R, Billi M, Canale M, Pasini L, Racanicchi S, Vagheggini A, et al: Prognostic role of circulating miRNAs in Early-stage non-small cell lung cancer. J Clin Med. 8:131–142. 2019. View Article : Google Scholar : | |
|
Wang Y, Yin W, Lin Y, Yin K, Zhou L, Du Y, Yan T and Lu J: Downregulated circulating microRNAs after surgery: Potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. Cell Death Discov. 4:2–8. 2018. View Article : Google Scholar | |
|
Kara M, Yumrutas O, Ozcan O, Celik OI, Bozgeyik E, Bozgeyik I and Tasdemir S: Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma. Gene. 567:81–86. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Spindler KL, Pallisgaard N, Vogelius I and Jakobsen A: Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 18:1177–1185. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, et al: Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: Results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol Hepatol. 3:635–643. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao H, Shen J, Hodges TR, Song R, Fuller GN and Heimberger AB: Serum microRNA profiling in patients with glioblastoma: A survival analysis. Mol Cancer. 16:59–70. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cooper J and Giancotti FG: Integrin signaling in cancer: Mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 35:347–367. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Friedmann Angeli JP, Krysko DV and Conrad M: Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 19:405–414. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tooker P, Yen WC, Ng SC, Negro-Vilar A and Hermann TW: Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 67:4425–4433. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Alvarez-Garcia I and Miska EA: MicroRNA functions in animal development and human disease. Development. 132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 18:74–82. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Sun X, Wang M, Hou Y, Zhan Y, Jiang Y, Liu Z, Cao X, Chen P, Chen X, et al: A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells. Gastroenterology. 147:847–859.e11. 2014. View Article : Google Scholar | |
|
Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Yu Z, Meng X, Zhou S, Xiao S, Li X, Liu S and Yu P: Long noncoding RNA GAS5 impairs the proliferation and invasion of endometrial carcinoma induced by high glucose via targeting miR-222-3p/p27. Am J Transl Res. 11:2413–2421. 2019.PubMed/NCBI | |
|
Paquet-Fifield S, Koh SL, Cheng L, Beyit LM, Shembrey C, Molck C, Behrenbruch C, Papin M, Gironella M, Guelfi S, et al: Tight junction protein Claudin-2 promotes Self-renewal of human colorectal cancer Stem-like cells. Cancer Res. 78:2925–2938. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Polk DB and Peek RM Jr: Helicobacter pylori: Gastric cancer and beyond. Nat Rev Cancer. 10:403–414. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ishiguro H, Kimura M and Takeyama H: Role of microRNAs in gastric cancer. World J Gastroenterol. 20:5694–5699. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ebert MS and Sharp PA: Roles for microRNAs in conferring robustness to biological processes. Cell. 149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D and Cheng JQ: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 291:31079–31086. 2016. View Article : Google Scholar | |
|
Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, et al: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sun K, Wang W, Zeng JJ, Wu CT, Lei ST and Li GX: MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin. 32:375–384. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Ma T, Yang S, Xia M, Xu J, An H, Yang Y and Li S: High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. Mol Cell Biochem. 357:363–371. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ying SY, Chang DC, Miller JD and Lin SL: The microRNA: Overview of the RNA gene that modulates gene functions. Methods Mol Biol. 342:1–18. 2006.PubMed/NCBI | |
|
Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M, et al: Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Hum Genet. 57:691–699. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ottley EC, Nicholson HD and Gold EJ: Activin A regulates microRNAs and gene expression in LNCaP cells. Prostate. 76:951–963. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J and Nemunaitis J: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 16:206–216. 2009. View Article : Google Scholar | |
|
Ottley EC, Nicholson HD and Gold EJ: Activin A regulates microRNAs and gene expression in LNCaP cells. Prostate. 76:951–963. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xu G, Wu J, Zhou L, Chen B, Sun Z, Zhao F and Tao Z: Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing. PLoS One. 5:e155192010. View Article : Google Scholar : PubMed/NCBI | |
|
Rihani A, Van Goethem A, Ongenaert M, De Brouwer S, Volders PJ, Agarwal S, De Preter K, Mestdagh P, Shohet J, Speleman F, et al: Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma. Sci Rep. 5:9027–9044. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Narrandes S and Xu W: Gene expression detection assay for cancer clinical use. J Cancer. 9:2249–2265. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bourboulia D and Stetler-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Wang X, Wang Y, Dai Y, Xie Y, Ping Y, Yin B, Yu P, Liu Z, Duan X, et al: SGK1 inhibition-induced autophagy impairs prostate cancer metastasis by reversing. EMT J Exp Clin Cancer Res. 37:732018. View Article : Google Scholar | |
|
Liu W, Wang X, Liu Z, Wang Y, Yin B, Yu P, Duan X, Liao Z, Chen Y, Liu C, et al: SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway. Br J Cancer. 117:1139–1153. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Indran IR, Tufo G, Pervaiz S and Brenner C: Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mavrogiannis A, Kokkinopoulou I, Kontos C and Sideris DJ: Effect of vinca alkaloids on the expression levels of microRNAs targeting apoptosis-related genes in breast cancer cell lines. Curr Pharm Biotechnol. 19:1076–1086. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O and Myklebust MP: Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. Oncotarget. 8:87837–87847. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tan HY, Wang N, Lam W, Guo W, Feng Y and Cheng YC: Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer. 17:43–52. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Vuong L, Kotecha RR, Voss MH and Hakimi AA: Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 9:1349–1357. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vitale I, Manic G, Coussens LM, Kroemer G and Galluzzi L: Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30:36–50. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou S, Liu R, Yuan K, Yi T, Zhao X, Huang C and Wei Y: Proteomics analysis of tumor microenvironment: Implications of metabolic and oxidative stresses in tumorigenesis. Mass Spectrom Rev. 32:267–311. 2013. View Article : Google Scholar | |
|
Ying X, Wu Q, Wu X, Zhu Q and Wang X, Jiang L, Chen X and Wang X: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macro-phages. Oncotarget. 7:43076–43087. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavo MR, Madonia S, Rossi M, Magro B, Rini F, et al: Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 71:265–273. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Degasperi E, D'Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M and Lampertico P: Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol. 17:1183–1191.e7. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, D'Offizi G, Capobianchi MR, Santoni A, Tripodi M and Agrati C: Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver Int. 38:1741–1750. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Varchetta S, Mele D, Mantovani S, Oliviero B, Cremonesi E, Ludovisi S, Michelone G, Alessiani M, Rosati R, Montorsi M and Mondelli MU: Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology. 56:841–849. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernandez-Rodriguez CM, Aleman S, Ganne-Carrie N, D'Ambrosio R, Pol S, et al: Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 66:485–493. 2017. View Article : Google Scholar | |
|
Fugier E, Marche H, Thélu MA, Macek Jilková Z, Van Campenhout N, Dufeu-Duchesne T, Leroy V, Zarski JP, Sturm N, Marche PN and Jouvin-Marche E: Functions of liver natural killer cells are dependent on the severity of liver inflammation and fibrosis in chronic hepatitis C. PLoS One. 9:e956142014. View Article : Google Scholar : PubMed/NCBI | |
|
Tölle A, Jung K, Friedersdorff F, Maxeiner A, Lein M, Fendler A and Stephan C: The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p. Cancer Biomark. Dec 15–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
|
Ryu K, Lee J, Choi M, Yoon S, Cho J, Ko Y, Shim J, Kim W, Park C and Kim SJ: Serum-derived exosomal MicroRNA profiles can predict poor survival outcomes in patients with extranodal natural Killer/T-cell lymphoma. Cancers (Basel). 12:35482020. View Article : Google Scholar | |
|
Zhai S, Xu Z, Xie J, Zhang J, Wang X, Peng C, Li H, Chen H, Shen B and Deng X: Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1. Oncogene. 40:277–291. 2021. View Article : Google Scholar : | |
|
Lu B, Sheng Y, Zhang J, Zheng Z and Ji L: The altered microRNA profile in andrographolide-induced inhibition of hepatoma tumor growth. Gene. 588:124–133. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gumbiner BM and Kim NG: The Hippo-YAP signaling pathway and contact inhibition of growth. J Cell Sci. 127:709–717. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Panneerselvam J, Srivastava A, Muralidharan R, Wang Q, Zheng W, Zhao L, Chen A, Zhao YD, Munshi A and Ramesh R: IL-24 modulates the high mobility group (HMG) A1/miR222/AKT signaling in lung cancer cells. Oncotarget. 7:70247–70263. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ignacio C, Mooney SM and Middleton FA: Effects of acute prenatal exposure to ethanol on microRNA expression are ameliorated by social enrichment. Front Pediatr. 2:1032014. View Article : Google Scholar : PubMed/NCBI | |
|
Théry C, Zitvogel L and Amigorena S: Exosomes: Composition, biogenesis and function. Nat Rev Immunol. 2:569–579. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pant S, Hilton H and Burczynski ME: The multifaceted exosome: Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol. 83:1484–1494. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kalluri R: The biology and function of exosomes in cancer. J Clin Invest. 126:1208–1215. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z and Yuan W: Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 17:1472018. View Article : Google Scholar : PubMed/NCBI | |
|
Han Z, Li Y, Zhang J, Guo C, Li Q, Zhang X, Lan Y, Gu W, Xing Z, Liang L, et al: Tumor-derived circulating exosomal miR-342-5p and miR-574-5p as promising diagnostic biomarkers for early-stage Lung Adenocarcino. Int J Med Sci. 17:1428–1438. 2020. View Article : Google Scholar : | |
|
Ortega MM and Bouamar H: Guidelines on designing MicroRNA sponges: From construction to stable cell line. Methods Mol Biol. 1509:221–233. 2017. View Article : Google Scholar | |
|
Wang Z: The guideline of the design and validation of MiRNA mimics. Methods Mol Biol. 676:211–223. 2011. View Article : Google Scholar | |
|
Arroyo J, Gallichotte E and Tewari M: Systematic design and functional analysis of artificial microRNAs. Nucleic Acids Res. 42:6064–6077. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC and Jaggi M: miRNA nanotherapeutics for cancer. Drug Discov Today. 22:424–432. 2017. View Article : Google Scholar : | |
|
Chen Y, Gao DY and Huang L: In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar | |
|
Bofill-De Ros X and Gu S: Guidelines for the optimal design of miRNA-based shRNAs. Methods. 103:157–166. 2016. View Article : Google Scholar : PubMed/NCBI |
